2.51

3.29% 0.08

After Hours: 2.50 -0.010 -0.40%

Spero Therapeutics Inc (SPRO)

Overview News Price History Option Chain Financials Discussions Forecast

Spero Therapeutics Inc stock is traded at $2.51, with a volume of 278.92K. It is up +3.29% in the last 24 hours and up +11.06% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Previous Close:

$2.43

Open:

$2.44

24h Volume:

278.92K

Relative Volume:

0.46

Market Cap:

$141.41M

Revenue:

$76.19M

Net Income/Loss:

$-1.61M

P/E Ratio:

251.00

EPS:

0.01

Net Cash Flow:

$28.98M

1W Performance:

+10.57%

1M Performance:

+11.06%

6M Performance:

-13.75%

1Y Performance:

+132.41%

1-Day Range:

$2.415

$2.52

1-Week Range:

$2.27

$2.52

52-Week Range:

$0.5052

$3.22

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name

Spero Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (625)

Phone

857-242-1600

Address

675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA

Employee

Twitter

@spero_tx

Next Earnings Date

2025-03-19

Latest SEC Filings

SPRO's Discussions on Twitter

Compare SPRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRO Spero Therapeutics Inc	2.51	136.90M	76.19M	-1.61M	28.98M	0.01
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight
Nov-27-17	Initiated	BofA/Merrill	Neutral
Nov-27-17	Initiated	Oppenheimer	Outperform
Nov-27-17	Initiated	Stifel	Buy

View All

Spero Therapeutics Inc Stock (SPRO) Latest News

Jan 03, 2026

Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Hold - MarketBeat

Jan 03, 2026

Jan 02, 2026

What analysts say about Spero Therapeutics Inc stockLong-Term Growth Stocks & Free Unmatched Market Gains - earlytimes.in

Jan 02, 2026

Dec 31, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World

Dec 31, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat

Dec 31, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Growth in Short Interest - MarketBeat

Dec 31, 2025

Dec 28, 2025

Book value per share of Spero Therapeutics, Inc. – BER:2HA - TradingView — Track All Markets

Dec 28, 2025

Dec 23, 2025

Spero Therapeutics (STU:2HA) EV-to-OCF : -2.75 (As of Dec. 24, 2025) - GuruFocus

Dec 23, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat

Dec 23, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average – Time to Sell? - Defense World

Dec 23, 2025

Dec 20, 2025

Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Growth Oriented Trade Recommendations - Улправда

Dec 20, 2025

Stop Loss: Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Reliable Price Breakout Signals - ulpravda.ru

Dec 20, 2025

Dec 19, 2025

GSK, Spero Therapeutics resubmits NDA for tebipenem HBr as oral option for complicated urinary tract infections - Contemporary OB/GYN

Dec 19, 2025

GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics - TipRanks

Dec 19, 2025

Spero Therapeutics Announces NDA Resubmission for Tebipenem HBr - TradingView — Track All Markets

Dec 19, 2025

Spero Therapeutics Announces GSK's NDA Resubmission for Tebipenem HBr, Triggering $25 Million Milestone Payment - Quiver Quantitative

Dec 19, 2025

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to - GlobeNewswire

Dec 19, 2025

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis - The Manila Times

Dec 19, 2025

How geopolitical risks impact Spero Therapeutics Inc. (2HA) stockMarket Performance Report & Short-Term Trading Opportunity Alerts - DonanımHaber

Dec 19, 2025

Dec 15, 2025

Total debt per share of Spero Therapeutics, Inc. – FWB:2HA - TradingView — Track All Markets

Dec 15, 2025

Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Dec 15, 2025

Dec 14, 2025

Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN

Dec 14, 2025

Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen - MarketBeat

Dec 14, 2025

Dec 06, 2025